Myome

MyOme: Clinical Whole Genome Analysis for Lifelong Health Insights

---

High-Level Overview

MyOme is a clinical whole genome analysis platform company that empowers families and individuals to understand their risk for inherited diseases. The company’s mission is to make meaningful, actionable genetic insights the standard of care by combining whole genome sequencing (WGS) with advanced bioinformatics and polygenic risk modeling. MyOme serves both patients and healthcare providers, offering comprehensive genetic screening and diagnostic tests that inform personalized prevention, lifestyle, and treatment decisions. Its platform is designed for seamless integration into routine clinical care, supporting primary care, concierge medicine, and employer-sponsored health programs.

MyOme’s growth momentum is evident in its expanding partnerships with leading health systems, research institutions, and employer benefit providers. The company has established itself as a leader in polygenic risk scoring, delivering insights for both rare and common diseases across diverse populations. Its CLIA-certified and CAP-accredited platform ensures clinical-grade reliability, while its focus on data privacy and patient ownership sets a high bar for ethical genomic medicine.

---

Origin Story

Founded in 2017 by a multidisciplinary team of experts in genomics, bioinformatics, and healthcare, MyOme emerged from a shared vision: to bridge the gap between cutting-edge genetic discoveries and real-world clinical impact. The founders recognized that while whole genome sequencing was becoming more accessible, most clinical applications still relied on limited gene panels or exome sequencing, missing the full spectrum of genetic risk. MyOme was built to unlock the full potential of the genome, providing lifelong, actionable insights for every individual.

Early traction came from partnerships with academic medical centers and large-scale population health initiatives, including collaborations with Broad Clinical Labs and the University of Alabama at Birmingham. These relationships validated MyOme’s approach and demonstrated the clinical utility of its integrated polygenic risk scores (iPRS™) across diverse ancestries. The company’s ability to deliver both rare disease diagnostics and proactive risk assessment for common conditions quickly positioned it as a pioneer in precision health.

---

Core Differentiators

• Whole Genome Sequencing (30x WGS): MyOme uses clinical-grade, 30x whole genome sequencing as the foundation for all its tests, enabling comprehensive detection of SNVs, indels, structural variants, and copy number changes—far beyond the reach of targeted panels.
• Integrated Polygenic Risk Scores (iPRS™): MyOme’s proprietary iPRS™ combines millions of genetic variants with clinical risk factors, delivering more accurate and personalized risk assessments for common diseases like cancer, heart disease, and diabetes.
• Blended Genome-Exome Sequencing (BGE): For select applications, MyOme offers BGE, which combines low-pass WGS with deeper exome coverage, maximizing both breadth and depth of variant detection from a single sample.
• Seamless Clinical Integration: The platform is designed for easy adoption in busy clinical settings, with end-to-end support, actionable reports, and access to genetic counseling.
• Data Privacy & Patient Ownership: MyOme prioritizes secure, portable genomic data that remains under the individual’s control, with strict policies against unauthorized use or sale.
• Validated Across Diverse Ancestries: MyOme’s risk models are trained and validated across diverse populations, including mixed ancestry, ensuring equitable access to precision medicine.

---

Role in the Broader Tech Landscape

MyOme is riding the wave of precision medicine and the democratization of genomic data. As healthcare systems increasingly prioritize preventive care and personalized treatment, the demand for comprehensive, clinically actionable genetic insights is growing rapidly. MyOme’s platform aligns with key trends: the shift from reactive to proactive health, the integration of genomics into routine care, and the expansion of employer-sponsored health benefits to include whole genome sequencing.

The timing is critical—advances in sequencing technology, bioinformatics, and polygenic risk modeling have made it possible to deliver meaningful insights at scale. MyOme is helping to narrow the gap between what is possible in genomics research and what is clinically accessible to patients. By partnering with health systems, employers, and research institutions, MyOme is shaping the future of population health and influencing how genetic data is used to improve outcomes.

---

Quick Take & Future Outlook

MyOme is poised to play a central role in the next generation of precision health. As genomic data becomes a routine part of medical records, MyOme’s platform will be essential for translating complex genetic information into actionable insights for patients and providers. The company is likely to expand its test menu, deepen its partnerships, and further integrate with electronic health records and digital health platforms.

Looking ahead, trends such as AI-driven risk prediction, long-read sequencing for rare disease diagnosis, and the growing demand for employer-sponsored genomic benefits will shape MyOme’s journey. The company’s commitment to equity, privacy, and clinical utility will continue to set it apart in a rapidly evolving landscape.

MyOme’s story began with a simple mission: to help families understand their genetic risk. Today, it is helping to redefine what is possible in personalized healthcare—making the whole genome a lifelong companion in the pursuit of better health.